Actively Recruiting
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Led by Medical University of Graz · Updated on 2025-11-21
1500
Participants Needed
12
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting and analyzing real-world data on treatment patterns, clinical outcomes, and side effects in adults with advanced pancreatic ductal adenocarcinoma (PDAC) in Austria. This observational study focuses on patients with locally advanced inoperable or metastatic PDAC who are receiving first-line chemotherapy as part of their palliative care. The study includes 1500 adult patients undergoing first-line chemotherapy with platinum- or gemcitabine-based regimens, including nal-Irinotecan/5-FU/Leukovorin for those with prior (neo)adjuvant therapy. Data will be collected on the use and impact of approved chemotherapeutic agents from second-line treatment and on various treatment patterns, molecular testing, and outcomes over a 24-month period. Participants will be monitored for clinical outcomes, treatment efficacy, and side effects such as neuropathy, anemia, nausea, and skin toxicity. The study also tracks treatment behaviors after disease progression, the use of tumor resection or metastasectomy, and the influence of factors like diabetes or genetic mutations. Researchers will analyze data to identify predictors of treatment success and adverse events, with the primary outcome focusing on the proportion of patients receiving second-line palliative therapy after progression on first-line treatment.
CONDITIONS
Brief Title
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older, any gender
- ECOG performance status of 0 to 2
- Histologically confirmed diagnosis of locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma
- Currently receiving or planned to receive palliative first-line chemotherapy with platinum- or gemcitabine-based regimens; patients receiving nal-Irinotecan/5-FU/Leukovorin as first-line after prior (neo)adjuvant therapy are also eligible
- Signed informed consent for prospective participants; retrospective cases do not require consent
You will not qualify if you...
- Patients with locally advanced operable pancreatic ductal adenocarcinoma who are not receiving palliative chemotherapy
- Patients with borderline resectable locally advanced pancreatic ductal adenocarcinoma who are not receiving palliative chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma undergoing first line chemotherapy are observed to evaluate treatment patterns and outcomes over time.
Visits according to routine clinical care with data collection on chemotherapy and outcomes
Trial Site Locations
Total: 12 locations
1
Medical University Graz Department of Oncology
Graz, Styria, Austria, 8036
Actively Recruiting
2
Ordensklinikum Linz
Linz, Upper Austria, Austria, 4010
Actively Recruiting
3
Landesklinikum Amstetten
Amstetten, Austria, 3300
Actively Recruiting
4
Landesklinikum Feldkirch
Feldkirch, Austria, 6800
Actively Recruiting
5
Krankenhaus der Barmherzigen Brüder
Graz, Austria, 8020
Actively Recruiting
6
Universitätsklinikum Innsbruck,
Innsbruck, Austria, 6020
Actively Recruiting
7
Landesklinikum Klagenfurt
Klagenfurt, Austria, 9020
Actively Recruiting
8
Universitätsklinikum St. Pölten
Sankt Pölten, Austria, 3100
Actively Recruiting
9
Barmherzige Schwestern Krankenhaus Wien
Vienna, Austria, 1060
Actively Recruiting
10
Pancreatic Cancer Unit des Comprehensive Cancer Center (CCC-PCU)
Vienna, Austria, 1090
Actively Recruiting
11
St. Josef Krankenhaus Wien
Vienna, Austria, 1130
Actively Recruiting
12
Krankenhaus St. Vinzenz Zams
Zams, Austria, 6511
Actively Recruiting
Research Team
A
Armin Gerger, Univ.Prof.Dr
K
Karin Groller, MPH
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here